GlobalData Plc

The global urology endoscopes market is set to rise from around $813 million in 2016 to $1.4 billion by 2023, representing a relatively strong compound annual growth rate (CAGR) of 8.4%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report on urology endoscopes, which include cystoscopes, resectoscopes, and ureteroscopes and covers 39 countries, states that these scopes are used for diagnosing and treating disorders related to the upper and lower urinary tract, including the management of stones in the kidney, ureter, and bladder, as well as urothelial tumors.

Vinie Varkey, MSc, Healthcare Analyst for GlobalData, explains: “One of the primary growth factors affecting the market is the technological advancement in optical imaging and product performance, helping urologists better diagnose and treat underlying causes of disease.

“For example, white light cystoscopy is the standard optical mode used to evaluate bladder urothelium. However, there are limitations associated with this technology because its visual determination of low grade and high grade cancer is unreliable. Recent optical imaging developments have helped to overcome this limitation, however, such as narrow-band imaging, which offers a high-resolution, wide-field view with enhanced visualization of mucosal and submucosal vasculature without the need to introduce a contrast dye.”

North America currently dominates the urology endoscopes market, and is expected grow at a CAGR of 10.7%, followed by the Asia-Pacific (APAC) region with a CAGR of 7.0%, and Europe with a CAGR of 5.1%. Regional adoption of urology endoscopes tends to depend on factors such as reimbursement, infrastructure capabilities, and the financial resources of healthcare settings in individual markets.

Varkey continues: “In North America, the primary driver of market growth is the increase in the number of urologic procedures caused by an increase in the prevalence and incidence of diseases affecting the urinary tract, particularly urolithiasis. According to GlobalData, the US dominates the region with an estimated market value of $273 million in 2016, followed by Canada and Mexico.

“The APAC region, meanwhile, has the potential to expand the overall market significantly, as there are increasing efforts from urologists to learn about new techniques and to adopt best practices in the management of urological diseases.”

  • The 39 major markets include the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India, South Korea, Australia, Canada, Mexico, Russia, Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Sweden, Switzerland, Turkey, Taiwan, New Zealand, Argentina, Chile, Egypt, Israel, Saudi Arabia, South Africa, and the United Arab Emirates.
Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Global glaucoma market to reach $3.8bn by 2026

    The total glaucoma market was estimated to be $2.6bn across the seven major markets (7MM*) in 2016. This is expected to grow to $3.8bn in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF